Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Arsenal Bridge Ventures is a venture capital firm founded in 2023 and based in Austin, Texas. The firm was established by Isaac Barchas, Jim Graham, and Jim Weiss, who collectively bring extensive experience in biotechnology business building and investing. Arsenal Bridge Ventures aims to advance biotechnology innovations, particularly from mid-continent research universities where commercial and venture networks are less developed.
The firm has evolved from its predecessor, Research Bridge Partners, which was co-founded by Barchas and Reid Hoffman. Arsenal Bridge Ventures currently manages multiple funds, including Arsenal Bridge Ventures II, II-B, III, and IV. The firm focuses on sourcing deals from underrepresented markets, emphasizing high-impact biotechnology innovations.
As of now, Arsenal Bridge Ventures has a portfolio of seven companies and is actively building its presence in the biotech sector. The firm’s unique geographic strategy allows it to tap into opportunities that are often overlooked by traditional biotech hubs.
Arsenal Bridge Ventures invests primarily in high-impact biotechnology innovations, with a specific emphasis on opportunities arising from mid-continent research universities. The firm employs a multifaceted investment strategy that includes leadership recruitment, capital deployment, and syndication to optimize asset value. Check sizes typically start at $7.8 million, allowing the firm to engage in meaningful investments at various stages, including Seed, Series A, and Series B.
The firm targets markets that are less crowded than traditional biotech hubs, such as Boston and San Francisco, which enables it to identify unique opportunities. Arsenal Bridge Ventures seeks to partner with founders who demonstrate strong leadership potential and innovative ideas. The firm’s investment thesis revolves around leveraging less saturated markets to source high-impact deals, particularly in the biotech and healthcare sectors.
Arsenal Bridge Ventures has a diverse portfolio of seven companies, showcasing its commitment to advancing biotechnology innovations. Notable portfolio companies include:
This portfolio reflects Arsenal Bridge Ventures' strategy of investing in companies that are positioned to make significant impacts in their respective fields.
Isaac Barchas — Founding Partner. He co-founded Research Bridge Partners and previously led the Austin Technology Incubator (ATI), bringing extensive experience in biotechnology business building.
Jim Graham — Founding Partner. He served as the Director of Investments at Research Bridge Partners' Catalyst Fund, contributing significant expertise in investment strategies.
Jim Weiss — Partner. He is the founder of Real Chemistry and has held positions at Genentech and Rhone-Poulenc Rorer, enhancing the firm's operational capabilities.
Reid Hoffman — Special Partner. Co-founder of LinkedIn and PayPal, he co-founded Research Bridge Partners and plays an active role in deal vetting and value creation.
Clay B. Siegall, PhD — Special Partner. Former CEO of Seagen, which was acquired by Pfizer for $43 billion in 2023, he currently serves as CEO of Immunome and contributes deep industry insights.
To pitch Arsenal Bridge Ventures, founders should use the preferred channel of their website at arsenalbridge.com or email info@arsenalbridge.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. Founders can expect a response within a few weeks, depending on the volume of inquiries.
Warm introductions are encouraged but not mandatory. The firm appreciates detailed pitches that clearly articulate the startup's vision and potential impact in the biotech sector.
In 2023, Arsenal Bridge Ventures was founded in Austin, Texas, with a focus on biotechnology innovations. The firm has been actively building its portfolio, which currently includes seven companies, such as Tetricus and Eradivir. Notably, MorphImmune and Novosteo are publicly traded companies on NASDAQ, validating the firm's investment thesis.
In May 2025, Arsenal Bridge Ventures made a significant investment in Courage Therapeutics, a University of Michigan spinout focused on obesity and eating disorders, with a seed investment of $7.8 million. The firm continues to emphasize its unique geographic strategy, sourcing deals from underdeveloped commercial networks in the mid-continent region.
What are Arsenal Bridge Ventures' investment criteria?
The firm focuses on high-impact biotechnology innovations, particularly from mid-continent research universities. They look for opportunities that demonstrate strong leadership potential and innovative solutions in the biotech and healthcare sectors.
How can founders apply or pitch to Arsenal Bridge Ventures?
Founders can pitch their ideas through the firm's website at arsenalbridge.com or by emailing info@arsenalbridge.com. It is recommended to include a detailed business plan and information about the team.
What makes Arsenal Bridge Ventures different from other VC firms?
Arsenal Bridge Ventures differentiates itself by focusing on biotechnology innovations from mid-continent research universities, targeting less saturated markets compared to traditional biotech hubs. This geographic strategy allows them to uncover unique investment opportunities.
What is the typical check size for investments?
The firm typically invests starting at $7.8 million, allowing them to engage in meaningful investments across various stages, including Seed, Series A, and Series B.
What is the firm's post-investment involvement like?
Arsenal Bridge Ventures actively supports its portfolio companies through strategic leadership recruitment and capital deployment. The firm leverages the extensive networks of its partners to enhance the growth potential of its investments.
What is the firm's approach to follow-on investments?
Arsenal Bridge Ventures is committed to supporting its portfolio companies through follow-on investments as they grow and scale, ensuring they have the necessary resources to succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.